small molecule

BAFIERTAM

MONOMETHYL FUMARATE

Loss of exclusivityFebruary 2035latest FDA-listed patent expiry
CompanyBANNER LIFE SCIENCES LLC

Drug detail

Brand nameBAFIERTAM
Active ingredientMONOMETHYL FUMARATE
Strength95MG
Dosage formCAPSULE, DELAYED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalApril 2020
Marketing statusRX

Listed patents

PatentExpiresType
11903918February 2035use U-1384
10918615February 2035product
10918616February 2035use U-1384
11590095February 2035use U-1384
9511043February 2035use U-1384
9326965February 2035use U-1384
9814692February 2035use U-1384
9636318February 2035use U-1384
9814691February 2035use U-1384
10105336February 2035product
9820961February 2035product
10098863February 2035product
9517209February 2035product
9566259February 2035product
9326947February 2035product
10105335February 2035product
10105337February 2035product
10918617February 2035product
9636319February 2035product
10945985February 2035product
9820960February 2035product

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

BAFIERTAM patent cliff — loss of exclusivity February 2035 | CliffBio